NCT05761951View on ClinicalTrials.gov

Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

60

Participants

Timeline

Start Date

August 29, 2023

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2029

Conditions

Endometrial Cancer

Interventions

DRUG

DKN-01

Given by IV (vein)

DRUG

Pembrolizumab

Given by IV (vein)

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Leap Therapeutics, Inc.

All Listed Sponsors

collaborator

Leap Therapeutics, Inc.

INDUSTRY

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER